Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Eris Lifesciences Q1 Review - Steady Outperformance Across Major Therapies: Motilal Oswal

The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its revenues from cardio-metabolic therapeutic segment, and has adopted a “Full Service” approach to diabetes management with a comprehensive range of oral anti-diabetic…

Eris Lifesciences enters licensing deal with Biocon for insulin glargine

Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 16, 2022.

Buy Eris Lifesciences; target of Rs 870: Motilal Oswal

Eris Lifesciences - Niche Launches To Aid Growth Over The Medium Term: Motilal Oswal

Eris Lifesciences Q4 Review - New Launches Scale-Up Holds Key: Prabhudas Lilladher

Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 05, 2022.

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated May 05, 2022.

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

In a BSE filing on Wednesday, Eris Lifesciences stated that the acquisition will be done for a total consideration of Rs 650 crore.

Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr

Eris Life Standalone March 2022 Net Sales at Rs 282.14 crore, up 9.85% Y-o-Y

The drug maker said the acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly owned subsidiary of Eris.

Eris acquires Oaknet Healthcare for Rs 650 crore to gain foothold in derma segment

Ventures Forays into dermatology and cosmetology therapies

Eris Lifesciences acquires Oaknet Healthcare for ₹650 crore

Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market

Eris Lifesciences Ltd

Eris Lifesciences Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Eris Lifesciences Q1 Review - Steady Outperformance Across Major Therapies: Motilal Oswal

Eris Lifesciences enters licensing deal with Biocon for insulin glargine

Buy Eris Lifesciences; target of Rs 870: Motilal Oswal

Eris Lifesciences - Niche Launches To Aid Growth Over The Medium Term: Motilal Oswal

Eris Lifesciences Q4 Review - New Launches Scale-Up Holds Key: Prabhudas Lilladher

Buy Eris Lifesciences; target of Rs 870: Motilal Oswal

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

Eris Lifesciences Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Eris Lifesciences Q1 Review - Steady Outperformance Across Major Therapies: Motilal Oswal

Eris Lifesciences enters licensing deal with Biocon for insulin glargine

Buy Eris Lifesciences; target of Rs 870: Motilal Oswal

Eris Lifesciences - Niche Launches To Aid Growth Over The Medium Term: Motilal Oswal

Eris Lifesciences Q4 Review - New Launches Scale-Up Holds Key: Prabhudas Lilladher

Buy Eris Lifesciences; target of Rs 870: Motilal Oswal

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock